Indian Study Finds Homeopathy Reduced ICU Admissions and Mortality in COVID-19 Patients
Peer-reviewed, double-blind clinical trial shows promising results when homeopathy is used
In May 2025, researchers in India published the results of a peer-reviewed, randomized, double-blind, placebo-controlled clinical trial investigating the use of individualized homeopathy as an adjuvant to standard care in the treatment of COVID-19.
A total of 269 participants who tested positive for COVID-19 (based on N Gene, ORF1ab Gene, and S Gene detection of SARS-CoV-2) were enrolled and randomized into two groups. One group received individualized homeopathic remedies alongside conventional treatment, while the control group received a placebo in addition to standard medical care.
Of the 269 participants, 133 (49%) were in the homeopathy group and 136 (51%) in the control group. At baseline, both groups were similar in terms of age, comorbidities, and allopathic treatment received.
Key Findings:
-
Symptoms including shortness of breath, cough, weakness, and fatigue showed significantly greater reduction in the homeopathy group by days 5 and 10.
-
There were no significant differences in inflammatory markers between the two groups.
-
Critically, the need for ICU admission (p = 0.01), ventilator support (p = 0.01), and mortality rate (p = 0.003) were all significantly lower in the group receiving homeopathy.
Conclusion:
The study concluded that homeopathy, when used as an adjunct to standard COVID-19 care *, was associated with reduced clinical symptoms and significantly lower rates of ICU admission, mechanical ventilation and death compared to standard care alone.
* The conventional therapy initially employed to treat COVID-19 patients included a combination of antipyretics such as paracetamol, acetylsalicylic acid, antimalarials (hydroxychloroquine), steroids (dexamethasone), antibiotics, and antiviral medications with or without non-invasive or invasive respiratory support, depending on the patient’s specific indications
While this trial was conducted under the “COVID-19” label, it’s important to acknowledge that widespread concerns have been raised about the accuracy and integrity of COVID-19 testing—particularly the overuse and manipulation of PCR cycle thresholds, which likely produced inflated case counts and misdiagnoses. Many researchers and clinicians have pointed out that what was labeled as “COVID” often mirrored common flu and cold symptoms.
In this context, the results of the study speak to more than just a single virus. They suggest that individualized homeopathy, used alongside standard care, may offer significant benefit in reducing the severity and complications of flu-like respiratory illnesses more broadly—including those triggered by other viruses or environmental factors. Whether or not one accepts the COVID-19 diagnosis as valid, the reduced ICU admissions, ventilator use, and mortality rates reported here are difficult to ignore.
Source: A randomized placebo controlled clinical trial using Homoeopathy as an adjuvant to standard care in the management of COVID-19, Advances in Integrative Medicine, 2025.
***************************************************************************************************************************